Quantification of the Plasma Concentrations of Perampanel Using High-Performance Liquid Chromatography and Effects of the CYP3A4*1G Polymorphism in Japanese Patients

Plasma concentration and clinical effects of perampanel—The Kork experience

(2019) Bernhard J. Steinhoff et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

A Liquid Chromatography-Mass Spectrometry Assay for Determination of Perampanel and Concomitant Antiepileptic Drugs in the Plasma of Patients With Epilepsy Compared With a Fluorescent HPLC Assay

(2018) Ugo de Grazia et al.   THERAPEUTIC DRUG MONITORING

Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters

(2017) Barry E. Gidal et al.   EPILEPSY RESEARCH

Therapeutic Drug Monitoring for Perampanel in Japanese Epilepsy Patients

(2017) Yoshiaki Yamamoto et al.   THERAPEUTIC DRUG MONITORING

Development and Validation of an HPLC-UV Assay for the Therapeutic Monitoring of the New Antiepileptic Drug Perampanel in Human Plasma

(2016) Valentina Franco et al.   THERAPEUTIC DRUG MONITORING

HPLC with fluorescence detection assay of perampanel, a novel AMPA receptor antagonist, in human plasma for clinical pharmacokinetic studies

(2015) Yuji Mano et al.   BIOMEDICAL CHROMATOGRAPHY

Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes

(2015) Patrick Kwan et al.   EPILEPSY RESEARCH

High-performance liquid chromatography–tandem mass spectrometry method for the determination of perampanel, a novel α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist in human plasma

(2015) Yuji Mano et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist

(2014) Philip N. Patsalos   EPILEPSIA

Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures

(2013) Barry E. Gidal et al.   EPILEPSIA

CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin

(2008) Yuan Gao et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY